Journal of Veterinary Science

  • 제22권6호
  • /
  • Pages.77.1-77.10
  • /
  • 2021
  • /
  • 1229-845X(pISSN)
  • /
  • 1976-555X(eISSN)
대한수의학회 (The Korean Society of Veterinary Science)
권호 표지
DOI QR코드

DOI QR Code

Evaluation of circulating IGF-I and IGFBP-3 as biomarkers for tumors in dogs

  • Song, Doo-Won (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Ro, Woong-Bin (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Sur, Jung-Hyang (Department of Veterinary Pathology, Small Animal Tumor Diagnostic Center, College of Veterinary Medicine, Konkuk University) ;
  • Seung, Byung-Joon (Department of Veterinary Pathology, Small Animal Tumor Diagnostic Center, College of Veterinary Medicine, Konkuk University) ;
  • Kang, Hyun-Min (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Kim, Jong-Won (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Park, See-Hyoung (Department of Biological and Chemical Engineering, Hongik University) ;
  • Park, Hee-Myung (Laboratory of Veterinary Internal Medicine, College of Veterinary Medicine, Konkuk University)
  • 투고 : 2021.06.16
  • 심사 : 2021.08.31
  • 발행 : 2021.11.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Serum-based parameters are considered non-invasive biomarkers for cancer detection. In human studies, insulin-like growth factor-I and II (IGF-I and IGF-II) and insulin-like growth factor binding protein-3 (IGFBP-3) are useful as diagnostic or prognostic markers and potential therapeutic targets. Objectives: This study examined the diagnostic utility of circulating IGF-I, IGF-II, and IGFBP-3 levels in healthy dogs and dogs with tumors. Methods: The serum concentrations of these biomarkers in 86 dogs with tumors were compared with those in 30 healthy dogs using an enzyme-linked immunosorbent assay (ELISA). Results: The ELISA results showed no difference between healthy dogs and dogs with tumors in the serum IGF-II concentrations. On the other hand, there was a significant difference in the circulating IGF-I and IGFBP-3 levels between healthy dogs and dogs with tumors. The concentrations of serum IGF-I (median [interquartile range], 103.4 [59.5-175] ng/mL) in dogs with epithelial tumors were higher than those (58.4 ng/mL [43.5-79.9]) in healthy dogs. Thus, the concentrations of serum IGFBP-3 (43.4 ng/mL [33.2-57.2]) in dogs with malignant mesenchymal tumors were lower than those (60.8 ng/mL [47.6-70.5]) in healthy dogs. Conclusions: The serum IGF-I and IGFBP-3 levels can be used as diagnostic biomarkers in dogs with tumors.

키워드

과제정보

We thank the members of our laboratory for the collection of samples used in this study. We also thank POBANILAB and BioSharp for technical assistance. The results of this study represent a part of the Ph.D. thesis by Doo-Won Song.

참고문헌

  1. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer. 2004;4(7):505-518. https://doi.org/10.1038/nrc1387
  2. Bergman D, Halje M, Nordin M, Engstrom W. Insulin-like growth factor 2 in development and disease: a mini-review. Gerontology. 2013;59(3):240-249. https://doi.org/10.1159/000343995
  3. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21(3):215-244. https://doi.org/10.1210/er.21.3.215
  4. Gerke I, Kaup FJ, Neumann S. 26S proteasome and insulin-like growth factor-1 in serum of dogs suffering from malignant tumors. Can J Vet Res. 2018;82(2):115-123.
  5. Jaillardon L, Abadie J, Godard T, Campone M, Loussouarn D, Siliart B, et al. The dog as a naturally-occurring model for insulin-like growth factor type 1 receptor-overexpressing breast cancer: an observational cohort study. BMC Cancer. 2015;15(1):664. https://doi.org/10.1186/s12885-015-1670-6
  6. Maniscalco L, Iussich S, Morello E, Martano M, Gattino F, Miretti S, et al. Increased expression of insulin-like growth factor-1 receptor is correlated with worse survival in canine appendicular osteosarcoma. Vet J. 2015;205(2):272-280. https://doi.org/10.1016/j.tvjl.2014.09.005
  7. McQuown B, Burgess KE, Heinze CR. Preliminary investigation of blood concentrations of insulin-like growth factor, insulin, lactate and β-hydroxybutyrate in dogs with lymphoma as compared with matched controls. Vet Comp Oncol. 2018;16(2):262-267. https://doi.org/10.1111/vco.12376
  8. Neumann S, Welling H, Thuere S. Insulin-like growth factor I concentration in dogs with inflammatory and neoplastic liver diseases. J Vet Med A Physiol Pathol Clin Med. 2007;54(10):612-617. https://doi.org/10.1111/j.1439-0442.2007.00982.x
  9. Szczubial M, Dabrowski R, Lopuszynski W, Bochniarz M, Krawczyk M, Urban-Chmiel R. Circulating concentrations of insulin like growth factor-1 in female dogs with spontaneous mammary tumours. Med Weter. 2018;74(3):167-170.
  10. Finotello R, Ressel L, Arvigo M, Baroni G, Marchetti V, Romanelli G, et al. Canine pancreatic islet cell tumours secreting insulin-like growth factor type 2: a rare entity. Vet Comp Oncol. 2016;14(2):170-180. https://doi.org/10.1111/vco.12085
  11. Rossi G, Errico G, Perez P, Rossi G, Paltrinieri S. Paraneoplastic hypoglycemia in a diabetic dog with an insulin growth factor-2-producing mammary carcinoma. Vet Clin Pathol. 2010;39(4):480-484. https://doi.org/10.1111/j.1939-165X.2010.00260.x
  12. Grimberg A. P53 and IGFBP-3: apoptosis and cancer protection. Mol Genet Metab. 2000;70(2):85-98. https://doi.org/10.1006/mgme.2000.3008
  13. Yamada PM, Lee KW. Perspectives in mammalian IGFBP-3 biology: local vs. systemic action. Am J Physiol Cell Physiol. 2009;296(5):C954-C976. https://doi.org/10.1152/ajpcell.00598.2008
  14. Hou YL, Luo P, Ji GY, Chen H. Clinical significance of serum IGFBP-3 in colorectal cancer. J Clin Lab Anal. 2019;33(6):e22912. https://doi.org/10.1002/jcla.22912
  15. Tas F, Bilgin E, Tastekin D, Erturk K, Duranyildiz D. Serum IGF-1 and IGFBP-3 levels as clinical markers for patients with lung cancer. Biomed Rep. 2016;4(5):609-614. https://doi.org/10.3892/br.2016.629
  16. Yoneyama T, Ohtsuki S, Honda K, Kobayashi M, Iwasaki M, Uchida Y, et al. Identification of IGFBP2 and IGFBP3 as compensatory biomarkers for CA19-9 in early-stage pancreatic cancer using a combination of antibody-based and LC-MS/MS-based proteomics. PLoS One. 2016;11(8):e0161009. https://doi.org/10.1371/journal.pone.0161009
  17. Jitpean S, Holst BS, Hoglund OV, Pettersson A, Olsson U, Strage E, et al. Serum insulin-like growth factor-I, iron, C-reactive protein, and serum amyloid A for prediction of outcome in dogs with pyometra. Theriogenology. 2014;82(1):43-48. https://doi.org/10.1016/j.theriogenology.2014.02.014
  18. Strage E, Lewitt M, Lilliehoo I, Stroom-Holst B, Jones B, Fall T. 46. Evaluation of an IGFBP-blocked ELISA for measuring IGF-I in canine serum. Vet Clin Pathol. 2011;40(4):587.
  19. Brunke MW, Frye CW, Levine CB, Hansen C, Wakshlag JJ. Insulin-like growth factor-1 and selected insulin-like growth factor binding protein concentrations during an ultramarathon sled dog race. Sci World J. 2016;2016:5686372. https://doi.org/10.1155/2016/5686372
  20. Dynkevich Y, Rother KI, Whitford I, Qureshi S, Galiveeti S, Szulc AL, et al. Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive. Endocr Rev. 2013;34(6):798-826. https://doi.org/10.1210/er.2012-1033
  21. Queiroga FL, Perez-Alenza D, Silvan G, Pena L, Lopes CS, Illera JC. Serum and intratumoural GH and IGF-I concentrations: prognostic factors in the outcome of canine mammary cancer. Res Vet Sci. 2010;89(3):396-403. https://doi.org/10.1016/j.rvsc.2010.03.016
  22. Braconi C, Bracci R, Bearzi I, Bianchi F, Sabato S, Mandolesi A, et al. Insulin-like growth factor (IGF) 1 and 2 help to predict disease outcome in GIST patients. Ann Oncol. 2008;19(7):1293-1298. https://doi.org/10.1093/annonc/mdn040
  23. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol. 1995;9(3):361-367. https://doi.org/10.1210/mend.9.3.7539889
  24. Johnson MA, Firth SM. IGFBP-3: a cell fate pivot in cancer and disease. Growth Horm IGF Res. 2014;24(5):164-173. https://doi.org/10.1016/j.ghir.2014.04.007
  25. Dunn SE, Kari FW, French J, Leininger JR, Travlos G, Wilson R, et al. Dietary restriction reduces insulinlike growth factor I levels, which modulates apoptosis, cell proliferation, and tumor progression in p53- deficient mice. Cancer Res. 1997;57(21):4667-4672.
  26. Hu Q, Zhou Y, Ying K, Ruan W. IGFBP, a novel target of lung cancer? Clin Chim Acta. 2017;466:172-177. https://doi.org/10.1016/j.cca.2017.01.017
  27. Mehta HH, Gao Q, Galet C, Paharkova V, Wan J, Said J, et al. IGFBP-3 is a metastasis suppression gene in prostate cancer. Cancer Res. 2011;71(15):5154-5163. https://doi.org/10.1158/0008-5472.CAN-10-4513
  28. Natsuizaka M, Kinugasa H, Kagawa S, Whelan KA, Naganuma S, Subramanian H, et al. IGFBP3 promotes esophageal cancer growth by suppressing oxidative stress in hypoxic tumor microenvironment. Am J Cancer Res. 2014;4(1):29-41.
  29. Le HT, Lee HJ, Cho J, Min HY, Lee JS, Lee SJ, et al. Insulin-like growth factor binding protein-3 exerts its anti-metastatic effect in aerodigestive tract cancers by disrupting the protein stability of vimentin. Cancers (Basel). 2021;13(5):1041. https://doi.org/10.3390/cancers13051041